PMID- 15870936
OWN - NLM
STAT- MEDLINE
DCOM- 20050919
LR  - 20201212
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 13
IP  - 6
DP  - 2005 Jun
TI  - Relative expression levels of Th1 and Th2 cytokine mRNA are independent 
      prognostic factors in patients with ovarian cancer.
PG  - 1153-8
AB  - The aim of the present study was to examine mRNA expression levels of Th1 
      (TNF-alpha , IFN-gamma, and IL-12p40) and Th2 (IL-6 and IL-10) cytokines for any 
      association with clinicopathological characteristics of epithelial ovarian 
      cancer. mRNA was isolated, and cDNA prepared from 40 samples of epithelial 
      ovarian cancers. Expression level of each cytokine mRNA was examined by the 
      real-time PCR technique (GAPDH gene, internal control). Expression ratio (target 
      gene/GAPDH) was used to evaluate gene expression. Results were analyzed against 
      clinical stage, histological grade, and histological type. Prognostic 
      significance of expression levels of each combination of Th1/Th2 values was 
      assessed. Tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma 
      (IFN-gamma) expression levels were significantly higher in serous adenocarcinoma 
      than in non-serous adenocarcinoma (p<0.05), but with no difference between 
      individual cytokine mRNA expression levels and clinical stage or histological 
      grade. Log-rank testing showed that high TNF-alpha mRNA expression (p=0.033) and 
      the diameter of largest residual lesion at initial surgery (p=0.012) 
      significantly correlate with longer survival in advanced stage (II/III/IV) 
      ovarian carcinomas. In examining all combinations of Th1/Th2 expression values, 
      the most significant association was between high IFN-gamma.IL-12p40/IL-6 
      expression levels and better prognosis in advanced stage (II/III/IV) ovarian 
      carcinomas (p=0.004). In multivariate analysis, high IFN-gamma.IL-12p40/IL-6 
      expression (p=0.009) and the diameter of residual lesion (p=0.011) remained 
      significantly associated with survival, whereas high TNF-alpha expression lost 
      significance. In conclusion, Th1 and Th2 cytokines might play an important role 
      in regulating the immune reaction in epithelial ovarian cancer cells. 
      IFN-gamma.IL-12p40/IL-6 expression may be a useful prognostic molecular marker 
      for patients with advanced ovarian cancer.
FAU - Kusuda, Tomoyo
AU  - Kusuda T
AD  - Department of Obstetrics and Gynecology, Hiroshima University Graduate School of 
      Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
FAU - Shigemasa, Kazushi
AU  - Shigemasa K
FAU - Arihiro, Koji
AU  - Arihiro K
FAU - Fujii, Tsuneo
AU  - Fujii T
FAU - Nagai, Nobutaka
AU  - Nagai N
FAU - Ohama, Koso
AU  - Ohama K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (DNA, Complementary)
RN  - 0 (Interleukin-12 Subunit p40)
RN  - 0 (Interleukin-6)
RN  - 0 (Protein Subunits)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Cystadenocarcinoma, Serous/genetics/metabolism/pathology
MH  - DNA, Complementary/genetics/metabolism
MH  - Female
MH  - Humans
MH  - Interferon-gamma/genetics/metabolism
MH  - Interleukin-10/genetics/metabolism
MH  - Interleukin-12/genetics/metabolism
MH  - Interleukin-12 Subunit p40
MH  - Interleukin-6/genetics/metabolism
MH  - Neoplasms, Glandular and Epithelial/genetics/*metabolism/pathology
MH  - Ovarian Neoplasms/genetics/*metabolism/pathology
MH  - Ovary/metabolism/pathology
MH  - Prognosis
MH  - Protein Subunits/genetics/metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Th1 Cells/*metabolism
MH  - Th2 Cells/*metabolism
MH  - Tumor Necrosis Factor-alpha/genetics/metabolism
EDAT- 2005/05/05 09:00
MHDA- 2005/09/20 09:00
CRDT- 2005/05/05 09:00
PHST- 2005/05/05 09:00 [pubmed]
PHST- 2005/09/20 09:00 [medline]
PHST- 2005/05/05 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2005 Jun;13(6):1153-8.